(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Step in Style: A Survey of \Solace and Execution on the Track\ Running Shoes - 2James Webb Space Telescope watches our Milky Way galaxy's monster black hole fire out a flare
- 3Instructions to Comprehend and Use Open Record Extra Offers
- 4Home Plan Tips for Seniors
- 5Figure out How to Alter Your Volvo XC40 for Further developed Solace
- Health officials report 14 Legionnaires' disease cases in Florida, gym connection suspected
- The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
- Sydney Sweeney is returning in 'The Housemaid's Secret': What to know about 'The Housemaid' sequel
- Parents who delay baby's first vaccines also likely to skip measles shots
- The Force of Organic product: 10 Assortments That Improve Your Wellbeing
- A Gastronomic Experience in Healthy Enjoyments: A Survey of \Nutritious and Tasty\ Solid Cooking Recipe Book
- 10 Moves toward Start Your Own Effective Business
- Everything you should know before booking a trip to Spain
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
